Peerview Neuroscience & Psychiatry Cme/cne/cpe Audio Podcast

Informações:

Sinopsis

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Episodios

  • Donna H. Ryan, MD, FTOS -Demystifying the Role of Incretin-Based Weight-Loss Pharmacotherapy: A Patient-Centered Approach to Overcoming Barriers and Addressing Underlying Causes of Obesity

    06/08/2021 Duración: 24min

    Go online to PeerView.com/XRQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in obesity reviews current evidence for incretin-based weight-loss pharmacotherapy and offers evidence-based approaches to individualizing care for patients with obesity. Upon completion of this accredited CE activity, participants should be better able to: Describe the pathophysiology of obesity and the role of weight-loss pharmacotherapy to address the metabolic adaptation that is related to weight loss, Evaluate recent evidence for current and emerging incretin-based weight-loss pharmacotherapies, including efficacy and safety data and anticipated effects in the context of obesity pathophysiology, Individualize the management of obesity consistent with current guidelines and in accordance with best practices in shared decision-making by incorporating incretin-based weight-loss pharmacotherapy as appropriate to overcome barriers to long-ter

  • Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors

    26/07/2021 Duración: 01h04s

    Go online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors for treating NF1-associated tumors, Evaluate the recent efficacy, safety, and tolerability data for MEK inhibitors and other targeted therapies for the treatment of NF1-associated tumors, Incorporate current and emerging innovative therapeutic options optimally for the management of NF1 and NF1-associated PNs and LGGs.

  • R. Robert Auger, MD, FAASM, FAPA, DABPN - The Dawn of a New Era: Recent Advances in the Pharmacologic Management of Idiopathic Hypersomnia

    07/07/2021 Duración: 36min

    Go online to PeerView.com/ETX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in sleep medicine discusses recent guidelines and evidence presented at the SLEEP 2021, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, on the pharmacologic management of idiopathic hypersomnia (IH). Upon completion of this accredited CE activity, participants should be better able to: Employ currently recommended approaches and available assessment tools to identify and differentially diagnose patients with IH, Incorporate the latest guideline recommendations and evidence for approved and emerging pharmacotherapies to optimize the management of patients with IH, Evaluate the clinical potential of recent advances in the pharmacologic treatment of patients with IH.

  • Loren D.M. Pena, MD, PhD - Advancing the Treatment of Pompe Disease: Clinical Updates in Newborn Screening and Enzyme Replacement

    30/06/2021 Duración: 23min

    Go online to PeerView.com/AFD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Pompe disease discusses the presentation of infantile- and late-onset Pompe disease, as well as treatment via enzyme replacement therapy. Upon completion of this accredited CE activity, participants should be better able to: Employ recommended assessments, including newborn screening (NBS), clinical presentation, and appropriate tests, to diagnose Pompe disease in a timely manner, Apply current recommendations and evidence regarding use of enzyme replacement therapy in the interdisciplinary management of Pompe disease, Recognize the potential role of emerging enzyme-replacement therapies in the treatment of Pompe disease.

  • Jinsy A. Andrews, MD, MSc, FAAN - A Visual Exploration of Antisense Oligonucleotide Therapies in Amyotrophic Lateral Sclerosis

    25/06/2021 Duración: 25min

    Go online to PeerView.com/DYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the use of antisense oligonucleotide therapies in patients with amyotrophic lateral sclerosis (ALS). Upon completion of this accredited CE activity, participants should be better able to: Identify common genes and cellular processes implicated in ALS pathogenesis, Recognize the mechanisms of action, efficacy, and safety profiles of emerging ALS therapies including antisense oligonucleotides, Discuss how the ALS treatment paradigm may change as a result of emerging therapies, Educate patients with ALS about ongoing clinical trials evaluating novel disease-modifying therapies.

  • Stuart H. Isaacson, MD - Managing Motor Complications in Parkinson’s Disease: Evaluating the Role of On-Demand Therapies for “Off” Episodes

    25/06/2021 Duración: 30min

    Go online to PeerView.com/BPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the management of motor complications in Parkinson’s disease. Upon completion of this accredited CE activity, participants should be better able to: Identify the need to adjust treatment for “off” episodes in Parkinson’s disease through symptom and therapy assessment and clear communication with patients and/or caregivers, Interpret evidence regarding on-demand treatment options and their role in the management of “off” episodes in Parkinson’s disease, Apply on-demand treatment options, based on current evidence, in the personalized management of “off” episodes in Parkinson’s disease.

  • Richard K. Bogan, MD, FCCP, FAASM - The Evolving Role of Oxybate Agents in the Management of Narcolepsy: A Visual Exploration of Individualized Care

    22/06/2021 Duración: 32min

    Go online to PeerView.com/MXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in sleep medicine discusses the signs and symptoms of narcolepsy and shares evidence-based approaches to individualizing care. Upon completion of this accredited CE activity, participants should be better able to: Apply criteria for the diagnosis of narcolepsy with or without cataplexy, Evaluate evidence regarding the role of oxybate formulations in the treatment of adults and children who have narcolepsy with or without cataplexy, including mechanistic effects on the underlying pathophysiology, Incorporate oxybate formulations as part of individualized regimens for treating narcolepsy, with or without cataplexy, considering comorbid conditions, disease burden, patient preferences, and quality of life.

  • Amit Bar-Or, MD, FRCPC / Ludwig Kappos, MD, FEAN, FAAN - The Rise of B-Cell Therapies in Relapsing MS: Examining the State of the Science, New Therapeutic Options, and Patient-Centered Clinical Decision-Making

    16/06/2021 Duración: 01h03min

    Go online to PeerView.com/WEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss treatment with B-cell therapies in patients with multiple sclerosis. Upon completion of this accredited CE activity, participants should be better able to: Describe the role of B cells in the pathogenesis of relapsing multiple sclerosis (MS), Recognize the similarities and differences between anti-CD20 monoclonal antibodies available for the treatment of relapsing forms of MS, Analyze available evidence on investigational B-cell–targeting therapies, Employ a patient-centered approach to treatment selection for patients with MS based on their disease activity, treatment preferences and goals, and therapeutic options.

  • Elizabeth A. Thiele, MD, PhD - Applying Evidence to Practice: Updated Consensus Recommendations for the Diagnosis, Surveillance, and Management of Tuberous Sclerosis Complex

    14/06/2021 Duración: 59min

    Go online to PeerView.com/EME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss recent updates to recommendations in the diagnosis, surveillance, and management of tuberous sclerosis complex. Upon completion of this activity, participants should be better able to: Utilize clinical and genetic diagnostic criteria to identify patients with tuberous sclerosis complex (TSC) early in the disease course, Employ updated consensus recommendations for the surveillance of patients with TSC throughout the course of their disease, Apply updated consensus recommendations for the management of patients with specific disease manifestations associated with TSC.

  • Benjamin W. Friedman, MD, MS, FAAEM, FACEP, FAHS - A New Era of Migraine Management: Recent Updates on Recognition, Acute Treatment, and Prevention for Emergency Physicians

    09/06/2021 Duración: 24min

    Go online to PeerView.com/VWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in emergency medicine discusses the diagnosis and management of patients with migraine in the emergency department setting. Upon completion of this accredited CE activity, participants should be better able to: Identify best practices and current recommendations for diagnosing patients with migraine, including risk-stratification strategies for performing a differential diagnosis in the emergency department (ED); Apply evidence-based criteria and screening tools to accurately diagnose patients presenting to the ED with migraine; Summarize data on the efficacy, safety, and tolerability of agents currently available for the acute treatment and prevention of migraine; Employ strategies to help coordinate outpatient care and integrate current therapies into personalized management plans for acute treatment and prevention of migraine.

  • Crystal M. Proud, MD - Data-Based Updates: Practical Application of Recent Evidence on Disease-Modifying Therapies for SMA

    07/06/2021 Duración: 35min

    Go online to PeerView.com/QQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the current clinical data and practical application of disease-modifying therapies in the management of patients with spinal muscular atrophy. Upon completion of this activity, participants should be better able to: Identify spinal muscular atrophy (SMA) through newborn screening and/or recognition of symptoms and signs, Apply current evidence on the efficacy, safety, and tolerability of approved disease-modifying therapies in the treatment of SMA, Counsel caregivers and/or patients regarding the need for monitoring and supportive care to optimize treatment outcomes in SMA.

  • Karl E. Anderson, MD - Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy

    02/06/2021 Duración: 31min

    Go online to PeerView.com/HKY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option. Upon completion of this activity, participants should be better able to: Recognize AHP and associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Describe evidence-based interventions for AHP, including the rationale and trial data for recently approved siRNA therapy, Apply evidence-based diagnostic and treatment approaches to minimize disease impact and burden for individuals with AHP.

  • Edward J. Fox, MD, PhD - A Visual Guide to B-Cell Therapies in Relapsing MS: Clarifying the Options in an Expanding Treatment Landscape

    07/05/2021 Duración: 26min

    Go online to PeerView.com/ZVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in multiple sclerosis discusses the role of B cells in MS pathogenesis and the use of anti-CD20 monoclonal antibodies in the management of relapsing forms of MS. Upon completion of this activity, participants should be better able to: Describe the role of B cells in the pathogenesis of relapsing multiple sclerosis (MS), Assess the mechanisms of action, safety, and efficacy of anti-CD20 monoclonal antibodies in the treatment of relapsing forms of MS, Apply best practices and clinical evidence when using B-cell–depleting therapies to optimize outcomes for patients with relapsing MS.

  • Marwan Sabbagh, MD, FAAN, CCRI - Expert Perspectives on the Early Diagnosis of Alzheimer’s Disease and the Promise of Novel Therapies on the Horizon

    05/05/2021 Duración: 01h01min

    Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world’s population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerVi

  • Kristina M. Deligiannidis, MD - Test Your Knowledge: The Evidence for GABA-Modulating Neuroactive Steroids as a New Class of Rapid-Acting Antidepressants

    04/05/2021 Duración: 23min

    Go online to PeerView.com/SZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the use of GABA-modulating neuroactive steroids as rapid-acting antidepressants. Upon completion of this activity, participants should be better able to: Discuss the role of GABAergic dysfunction in PPD and MDD and the rationale for therapeutic targeting of GABA-A receptors with neuroactive steroids; Review the current treatment landscape and unmet needs of patients with MDD; Identify key barriers to the diagnosis and management of PPD; Apply recent evidence on the efficacy and safety of approved and emerging neuroactive steroids to the management of patients with PPD and MDD.

  • Anne H. Cross, MD, FAAN / Prof. Xavier Montalban - Exploring the Rationale, Results, and Real-World Clinical Potential of BTK Inhibitors in the Management of Multiple Sclerosis

    22/02/2021 Duración: 49min

    Go online to PeerView.com/BTV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple sclerosis (MS) is associated with complex pathophysiology and numerous management challenges, resulting in the need for a full and diverse range of treatment options. Bruton tyrosine kinase (BTK) inhibitors hinder actions of B cells and resident CNS innate immune cells (microglia) that can contribute to neuroinflammation and neurodegeneration and ultimately lead to disease progression and disability. Based on these mechanisms, BTK inhibitors have the potential to improve outcomes related to inflammation and neurodegeneration. In this PeerView educational activity based on a recent live web broadcast, our experts offer insights into the rationale for using BTK inhibitors to treat MS, current evidence regarding the use of BTK inhibitors in the treatment of MS, and the potential role of BTK inhibitors for individualized MS management based on available evidence and patient

  • Steven Brem, MD - Rethinking Glioblastoma Care in an Evolving Therapeutic Landscape: Expert Perspectives on Modern Modalities, Novel Agents, and Combinations

    17/02/2021 Duración: 01h04min

    Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma mana

  • Maria K. Houtchens, MD, MMs - MS Treatment Decisions Before, During, and After Pregnancy: Focus on the Use of Disease-Modifying Therapies

    10/02/2021 Duración: 38min

    Go online to PeerView.com/MUD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy. Upon completion of this activity, participants should be better able to: Apply current guidelines, expert recommendations, and evidence for the management of MS in women before, during, and after pregnancy, Describe the influence of MS on pregnancy (eg, pregnancy outcomes) and of pregnancy on MS (eg, disease progression), Assess the safety and efficacy of disease-modifying therapies (DMTs) before, during, and after pregnancy in women with MS, Incorporate shared decision-making strategies to personalize care of women with MS throughout their family planning journey.

  • John Ravits, MD - Improving Outcomes in ALS Through Early Diagnosis and Emerging Targeted Therapies

    05/02/2021 Duración: 29min

    Go online to PeerView.com/XVB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses early diagnosis and emerging targeted therapies in the treatment of patients with amyotrophic lateral sclerosis (ALS). Upon completion of this activity, participants should be better able to: Apply established criteria to detect and diagnose patients with amyotrophic lateral sclerosis (ALS) early in the disease course, Recognize common genetic mutations that can cause ALS in patients with and without a family history of ALS, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of ALS, Identify the potential impact of emerging therapies on the future management of genetic subtypes of ALS.

  • Bruce Cree, MD, PhD, MAS - Provider Perspectives on Current and Emerging Disease-Modifying Treatments for Multiple Sclerosis

    20/01/2021 Duración: 18min

    Go online to PeerView.com/JFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert neurologist discusses new disease-modifying therapies for multiple sclerosis. Upon completion of this activity, participants should be better able to: Apply the latest efficacy, safety, and tolerability data for approved disease-modifying therapies in individualized management of patients with multiple sclerosis, Discuss emerging data for newly approved disease-modifying therapies for the treatment of multiple sclerosis.

página 1 de 3